Tim Rhines, Ph.D., Joins Lachman Consultants as a Director in the Science and Technology Practice

Timothy Rhines, Ph.D. is a Director in the Science & Technology Practice at Lachman Consultants who is a seasoned CMC pharmaceutical / biopharmaceutical professional with more than 27 years directing CMC activities, leading analytical chemistry teams, addressing compliance gaps, compliance department leadership with P&L responsibility, implementing process excellence initiatives, developing pharmaceutical product stability operations, and CMC project management.

Lachman Consultants to Offer Insights on Future Transition of Biological Products at the 2019 Parenteral Drug Association (PDA) Annual Meeting

(Westbury, NY – February 2019) Lachman Consultant Services, Inc., a leading provider of expert compliance, regulatory affairs and technical services to life sciences organizations worldwide will be a Bronze Sponsor at the 2019 Annual Meeting of the Parenteral Drug Association (PDA), Booth #308, March 11-13, at the Marriott Marquis San Diego, San Diego, CA. Themed “Solving Manufacturing and Supply Challenges for Current and Future Medicinal Products,” the PDA’s flagship Annual Meeting provides a venue for obtaining the latest information on parenteral processing,

Lachman Consultants Services, Inc. Announces Business Exposition Sponsorship of Access! 2019

While concluding its 40th Anniversary Celebration Year with the start of 2019, Lachman Consultants recently announced participation as Business Exposition Sponsor of ACCESS! 2019, the annual meeting of the Association for Accessible Medicines (AAM).

(Westbury, NY – January 2019) Lachman Consultant Services, Inc. a leading provider of expert compliance, regulatory affairs and technical services to life sciences clients worldwide will be a prominent participant at ACCESS!

Happy Holidays from Us to You!

To all of our readers – Have a happy holiday season and a very happy, healthy, and prosperous New Year.  The Lachman blog will be taking a break over the holiday starting Friday, December 21st (unless something extremely urgent occurs) and I hope that all of you will rejoin me in the New Year as we follow the ever-changing landscape of FDA regulatory science,

Fran Zipp Elected Vice Chair of ISPE International Board of Directors

LCS would like to congratulate the newly elected International Board of Directors for ISPE for 2018-2019. This Board is responsible for devising strategy and governance of ISPE, the International Society for Pharmaceutical Engineering, is the world’s largest not-for-profit association serving its Members by leading scientific, technical and regulatory advancement throughout the entire pharmaceutical lifecycle. The newly elected Board includes LCS’ own CEO and President,

Keith Webber, Ph.D., new Vice President, Biotechnology at Lachman Consultant Services, Inc.

We are pleased to announce that Keith Webber, Ph.D. has accepted the position of Vice President, Biotechnology at Lachman Consultants, effective September 1, 2018.

Dr. Webber delivers scientific direction, strategic guidance, and leadership regarding biotechnology products, new drugs, and generic drugs, based on his 30+ years of combined industry, U.S. FDA, and NIH experience. 

Lori-Ann Woodard, new Director, Medical Device at Lachman Consultant Services, Inc.

We are pleased to announce that Lori-Ann Woodard has accepted the position of Director, Medical Device at Lachman Consultants, effective August 20, 2018.

Ms. Woodard delivers expertise in the implementation and management of Quality Management Systems for medical devices, Software as a Medical Device (SaMD), and combination products. She has more than 20 years of experience that includes building QMS and cGMP quality systems from the ground up,

Aloka Srinivasan, Ph.D., New Vice President, Regulatory Practice at Lachman Consultant Services, Inc.

We are pleased to announce that Aloka Srinivasan has accepted the position of Vice President, Regulatory Practice at Lachman Consultants, effective May 14, 2018.

Dr. Srinivasan is a recognized professional with more than 15 years of experience serving at FDA and National Cancer Institute where she contributed to: establishing a DMF review division in FDA to meet GDUFA related goals;

We are pleased to announce that Linda Evans O’Connor has been promoted to VP, Chief of Staff.

In her new role, Linda will directly support the President and CEO serving as principal interface in key matters and delivering oversight across all Practice Areas, including program management of existing, new, and evolving projects. She will assist in the development of strategic plans and goals, advise on projects and critical issues, and continue to direct the on-going development of the Lachman brand and marketing strategy.